Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1992 Apr;60(4):1536–1543. doi: 10.1128/iai.60.4.1536-1543.1992

Shiga toxin-associated hemolytic uremic syndrome: combined cytotoxic effects of shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro.

C B Louise 1, T G Obrig 1
PMCID: PMC257028  PMID: 1548077

Abstract

This study explores the in vitro relationship between Shiga toxin-producing Shigella spp. and Escherichia coli and the development of vascular complications in humans following bacillary dysentery. We propose that lipopolysaccharide (LPS; endotoxin) may combine with Shiga toxin to facilitate vascular damage characteristic of hemolytic uremic syndrome. We have examined the direct cytotoxic effects of Shiga toxin and LPS on human umbilical vein endothelial cells (HUVEC) in culture. Shiga toxin alone was cytotoxic to HUVEC, whereas LPS was noncytotoxic at concentrations at or below 10 micrograms/ml. Combinations of LPS with Shiga toxin resulted in a synergistic cytotoxic effect. The synergistic cytotoxic response of HUVEC to Shiga toxin plus LPS was dose dependent for both agents and was maximal at 24 h of exposure. This synergistic response was enhanced by preincubation of HUVEC with LPS. LPS (1 micrograms/ml) alone depressed HUVEC protein synthesis in a transient manner and enhanced the protein synthesis-inhibiting activity of Shiga toxin. The synergistic cytotoxic activity of LPS analogs was as follows, in decreasing order: complete LPS = diphosphoryl lipid A greater than monophosphoryl lipid A greater than deacylated LPS. These results are consistent with a role for Shiga toxin and LPS in the development of hemolytic uremic syndrome at the level of the vascular endothelium in humans.

Full text

PDF
1536

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boyd B., Lingwood C. Verotoxin receptor glycolipid in human renal tissue. Nephron. 1989;51(2):207–210. doi: 10.1159/000185286. [DOI] [PubMed] [Google Scholar]
  2. Cantey J. R. Shiga toxin--an expanding role in the pathogenesis of infectious diseases. J Infect Dis. 1985 May;151(5):766–771. doi: 10.1093/infdis/151.5.766. [DOI] [PubMed] [Google Scholar]
  3. Ding H. F., Nakoneczna I., Hsu H. S. Protective immunity induced in mice by detoxified salmonella lipopolysaccharide. J Med Microbiol. 1990 Feb;31(2):95–102. doi: 10.1099/00222615-31-2-95. [DOI] [PubMed] [Google Scholar]
  4. Dodds K. L., Perry M. B., McDonald I. J. Alterations in lipopolysaccharide produced by chemostat-grown Escherichia coli O157:H7 as a function of growth rate and growth-limiting nutrient. Can J Microbiol. 1987 May;33(5):452–458. doi: 10.1139/m87-075. [DOI] [PubMed] [Google Scholar]
  5. Fong J. S., de Chadarevian J. P., Kaplan B. S. Hemolytic-uremic syndrome. Current concepts and management. Pediatr Clin North Am. 1982 Aug;29(4):835–856. doi: 10.1016/s0031-3955(16)34216-x. [DOI] [PubMed] [Google Scholar]
  6. Fontaine A., Arondel J., Sansonetti P. J. Role of Shiga toxin in the pathogenesis of bacillary dysentery, studied by using a Tox- mutant of Shigella dysenteriae 1. Infect Immun. 1988 Dec;56(12):3099–3109. doi: 10.1128/iai.56.12.3099-3109.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. GIANANTONIO C., VITACCO M., MENDILAHARZU F., RUTTY A., MENDILAHARZU J. THE HEMOLYTIC-UREMIC SYNDROME. J Pediatr. 1964 Apr;64:478–491. doi: 10.1016/s0022-3476(64)80337-1. [DOI] [PubMed] [Google Scholar]
  8. Harlan J. M., Harker L. A., Striker G. E., Weaver L. J. Effects of lipopolysaccharide on human endothelial cells in culture. Thromb Res. 1983 Jan 1;29(1):15–26. doi: 10.1016/0049-3848(83)90121-4. [DOI] [PubMed] [Google Scholar]
  9. Jaffe E. A., Nachman R. L., Becker C. G., Minick C. R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973 Nov;52(11):2745–2756. doi: 10.1172/JCI107470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kaplan B. S., Cleary T. G., Obrig T. G. Recent advances in understanding the pathogenesis of the hemolytic uremic syndromes. Pediatr Nephrol. 1990 May;4(3):276–283. doi: 10.1007/BF00857676. [DOI] [PubMed] [Google Scholar]
  11. Karmali M. A. Infection by verocytotoxin-producing Escherichia coli. Clin Microbiol Rev. 1989 Jan;2(1):15–38. doi: 10.1128/cmr.2.1.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Karmali M. A., Petric M., Lim C., Fleming P. C., Arbus G. S., Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis. 1985 May;151(5):775–782. doi: 10.1093/infdis/151.5.775. [DOI] [PubMed] [Google Scholar]
  13. Karmali M. A., Steele B. T., Petric M., Lim C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet. 1983 Mar 19;1(8325):619–620. doi: 10.1016/s0140-6736(83)91795-6. [DOI] [PubMed] [Google Scholar]
  14. Koster F. T., Boonpucknavig V., Sujaho S., Gilman R. H., Rahaman M. M. Renal histopathology in the hemolytic-uremic syndrome following shigellosis. Clin Nephrol. 1984 Feb;21(2):126–133. [PubMed] [Google Scholar]
  15. Koster F., Levin J., Walker L., Tung K. S., Gilman R. H., Rahaman M. M., Majid M. A., Islam S., Williams R. C., Jr Hemolytic-uremic syndrome after shigellosis. Relation to endotoxemia and circulating immune complexes. N Engl J Med. 1978 Apr 27;298(17):927–933. doi: 10.1056/NEJM197804272981702. [DOI] [PubMed] [Google Scholar]
  16. Levine M. M., DuPont H. L., Formal S. B., Hornick R. B., Takeuchi A., Gangarosa E. J., Snyder M. J., Libonati J. P. Pathogenesis of Shigella dysenteriae 1 (Shiga) dysentery. J Infect Dis. 1973 Mar;127(3):261–270. doi: 10.1093/infdis/127.3.261. [DOI] [PubMed] [Google Scholar]
  17. Lindberg A. A., Kärnell A., Weintraub A. The lipopolysaccharide of Shigella bacteria as a virulence factor. Rev Infect Dis. 1991 Mar-Apr;13 (Suppl 4):S279–S284. doi: 10.1093/clinids/13.supplement_4.s279. [DOI] [PubMed] [Google Scholar]
  18. Loppnow H., Brade H., Dürrbaum I., Dinarello C. A., Kusumoto S., Rietschel E. T., Flad H. D. IL-1 induction-capacity of defined lipopolysaccharide partial structures. J Immunol. 1989 May 1;142(9):3229–3238. [PubMed] [Google Scholar]
  19. Louise C. B., Obrig T. G. Shiga toxin-associated hemolytic-uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1 beta, and tumor necrosis factor alpha on human vascular endothelial cells in vitro. Infect Immun. 1991 Nov;59(11):4173–4179. doi: 10.1128/iai.59.11.4173-4179.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Magnuson D. K., Weintraub A., Pohlman T. H., Maier R. V. Human endothelial cell adhesiveness for neutrophils, induced by Escherichia coli lipopolysaccharide in vitro, is inhibited by Bacteroides fragilis lipopolysaccharide. J Immunol. 1989 Nov 1;143(9):3025–3030. [PubMed] [Google Scholar]
  21. Moore K. L., Andreoli S. P., Esmon N. L., Esmon C. T., Bang N. U. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest. 1987 Jan;79(1):124–130. doi: 10.1172/JCI112772. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Newton R. C. Human monocyte production of interleukin-1: parameters of the induction of interleukin-1 secretion by lipopolysaccharides. J Leukoc Biol. 1986 Mar;39(3):299–311. doi: 10.1002/jlb.39.3.299. [DOI] [PubMed] [Google Scholar]
  23. O'Brien A. D., Holmes R. K. Shiga and Shiga-like toxins. Microbiol Rev. 1987 Jun;51(2):206–220. doi: 10.1128/mr.51.2.206-220.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Obrig T. G., Del Vecchio P. J., Brown J. E., Moran T. P., Rowland B. M., Judge T. K., Rothman S. W. Direct cytotoxic action of Shiga toxin on human vascular endothelial cells. Infect Immun. 1988 Sep;56(9):2373–2378. doi: 10.1128/iai.56.9.2373-2378.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Obrig T. G., Moran T. P., Brown J. E. The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesis. Biochem J. 1987 Jun 1;244(2):287–294. doi: 10.1042/bj2440287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Pohlman T. H., Harlan J. M. Human endothelial cell response to lipopolysaccharide, interleukin-1, and tumor necrosis factor is regulated by protein synthesis. Cell Immunol. 1989 Mar;119(1):41–52. doi: 10.1016/0008-8749(89)90222-0. [DOI] [PubMed] [Google Scholar]
  27. Raghu G., Striker L. J., Striker G. E. Lipopolysaccharide-mediated injury to cultured human glomerular endothelial cells. Clin Immunol Immunopathol. 1986 Mar;38(3):275–281. doi: 10.1016/0090-1229(86)90237-0. [DOI] [PubMed] [Google Scholar]
  28. Raghupathy P., Date A., Shastry J. C., Sudarsanam A., Jadhav M. Haemolytic-uraemic syndrome complicating shigella dystentery in south Indian children. Br Med J. 1978 Jun 10;1(6126):1518–1521. doi: 10.1136/bmj.1.6126.1518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Richardson S. E., Karmali M. A., Becker L. E., Smith C. R. The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. Hum Pathol. 1988 Sep;19(9):1102–1108. doi: 10.1016/s0046-8177(88)80093-5. [DOI] [PubMed] [Google Scholar]
  30. Riddell R. J., Clothier R. H., Balls M. An evaluation of three in vitro cytotoxicity assays. Food Chem Toxicol. 1986 Jun-Jul;24(6-7):469–471. doi: 10.1016/0278-6915(86)90095-5. [DOI] [PubMed] [Google Scholar]
  31. Riedo F. X., Munford R. S., Campbell W. B., Reisch J. S., Chien K. R., Gerard R. D. Deacylated lipopolysaccharide inhibits plasminogen activator inhibitor-1, prostacyclin, and prostaglandin E2 induction by lipopolysaccharide but not by tumor necrosis factor-alpha. J Immunol. 1990 May 1;144(9):3506–3512. [PubMed] [Google Scholar]
  32. Sherman P., Soni R., Karmali M. Attaching and effacing adherence of Vero cytotoxin-producing Escherichia coli to rabbit intestinal epithelium in vivo. Infect Immun. 1988 Apr;56(4):756–761. doi: 10.1128/iai.56.4.756-761.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Takayama K., Qureshi N., Ribi E., Cantrell J. L. Separation and characterization of toxic and nontoxic forms of lipid A. Rev Infect Dis. 1984 Jul-Aug;6(4):439–443. doi: 10.1093/clinids/6.4.439. [DOI] [PubMed] [Google Scholar]
  34. Tesh V. L., Samuel J. E., Perera L. P., Sharefkin J. B., O'Brien A. D. Evaluation of the role of Shiga and Shiga-like toxins in mediating direct damage to human vascular endothelial cells. J Infect Dis. 1991 Aug;164(2):344–352. doi: 10.1093/infdis/164.2.344. [DOI] [PubMed] [Google Scholar]
  35. Wharram B. L., Fitting K., Kunkel S. L., Remick D. G., Merritt S. E., Wiggins R. C. Tissue factor expression in endothelial cell/monocyte cocultures stimulated by lipopolysaccharide and/or aggregated IgG. Mechanisms of cell:cell communication. J Immunol. 1991 Mar 1;146(5):1437–1445. [PubMed] [Google Scholar]
  36. Wright S. D. Multiple receptors for endotoxin. Curr Opin Immunol. 1991 Feb;3(1):83–90. doi: 10.1016/0952-7915(91)90082-c. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES